Cost-effectiveness analysis of tofacitinib compared with adalimumab and etanercept in the treatment of severe active rheumatoid arthritis; Iranian experience

References

• Singh JA, Saag KG, Bridges SL, et al. American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol (Hoboken, N.J.) [Internet]. 2015;2016(68):1–26. DOI:10.1002/acr.22783
   Web of Science ®Google Scholar
• Aletaha D, Neogi T, Silman AJ, et al. Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum [Internet]. 2010;62:2569–2581. [Cited 2018 Apr 25]. DOI:10.1002/art.27584
   Web of Science ®Google Scholar
• Gibofsky A. Epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis: A synopsis. Am J Manag Care. 2014;20:S128–135. Available from:http://www.ncbi.nlm.nih.gov/pubmed/25180621.
   Web of Science ®Google Scholar
• Yazdany J, Dudley RA, Chen R, et al. Coverage for high-cost specialty drugs for rheumatoid arthritis in medicare part D. Arthritis Rheumatol. 2015;67:1474–1480.
   PubMed Web of Science ®Google Scholar
• Cisternas MG, Murphy LB, Yelin EH, et al. Trends in medical care expenditures of US adults with arthritis and other rheumatic conditions 1997 to 2005. J Rheumatol. 2009;36:2531–2538.
   PubMed Web of Science ®Google Scholar
• Cush JJ. Early rheumatoid arthritis - Is there a window of opportunity? J Rheumatol. 2007;34:1–7.
   PubMed Web of Science ®Google Scholar
• Lard LR, Visser H, Speyer I, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med. 2001;111:446–451.
   PubMed Web of Science ®Google Scholar
• Anderson J, Caplan L, Yazdany J, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken) [Internet]. 2012;64:640–647.
   PubMed Web of Science ®Google Scholar
• Bays AM, Gardner G. Pharmacologic therapies for rheumatologic and autoimmune conditions. Med Clin North Am. 2016;100:719–731.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis [Internet]. 2020; annrheumdis-2019-216655. Available from: http://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2019-216655
   Web of Science ®Google Scholar
• Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: A critical review. Arthritis Res Ther. 2009;11:S1.
   PubMed Web of Science ®Google Scholar
• Claxton L, Jenks M, Taylor M, et al. An economic evaluation of tofacitinib treatment in rheumatoid arthritis: modeling the cost of treatment strategies in the United States. J Manag Care Spec Pharm. 2016;22:1088–1102.
   PubMedGoogle Scholar
• Van Der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65:559–570.
   PubMed Web of Science ®Google Scholar
• Carlson JJ, Ogale S, Dejonckheere F, et al. Economic evaluation of tocilizumab monotherapy compared to adalimumab monotherapy in the treatment of severe active rheumatoid arthritis. Value Heal. 2015;18:173–179.
   PubMed Web of Science ®Google Scholar
• Claxton L, Taylor M, Gerber RA, et al. Modelling the cost-effectiveness of tofacitinib for the treatment of rheumatoid arthritis in the United States. Curr Med Res Opin [Internet]. 2018;34:1991–2000.
   PubMed Web of Science ®Google Scholar
• Lee MY, Park SK, Park SY, et al. Cost-effectiveness of tofacitinib in the treatment of moderate to severe rheumatoid arthritis in South Korea. Clin Ther. 2015;37:1662–1676.e2.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964–975.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017;390:457–468.
   PubMed Web of Science ®Google Scholar
• Bruce B, Fries JF. The stanford health assessment questionnaire: A review of its history, issues, progress, and documentation. J Rheumatol. 2003;30:167–178.
   PubMed Web of Science ®Google Scholar
• Brennan A, Bansback N, Reynolds A, et al. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology. 2004;43:62–72.
   PubMed Web of Science ®Google Scholar
• Institute for Clinical and Economic Review (ICER). Targeted immune modulators for rheumatoid arthritis: effectiveness & value. Inst Clin Econ Rev. [Internet]. 2017;ES19. Available from: https://icer-review.org/wp-content/uploads/2016/08/NECEPAC_RA_Evidence_Report_Final_040717.pdf.
   Google Scholar
• Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017;390:457–468.
   PubMed Web of Science ®Google Scholar
• Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.[see comment]. Lancet [Internet]. 2004;363:675–681. Available from: http://ac.els-cdn.com/S0140673604156407/1-s2.0-S0140673604156407-main.pdf?_tid=8d558254-70a4-11e4-8c81-00000aacb362&acdnat=1416481457_fb1f2eb7a85fc004f2485b652844b250%5Cnhttp://www.ncbi.nlm.nih.gov/pubmed/15001324http://www.thelancet.com/journals/lancet/a
   PubMed Web of Science ®Google Scholar
• Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793–2806.
   PubMed Web of Science ®Google Scholar
• Kazlauskiene V, Stundziene A. Estimation of social discount rate for Lithuania. Trends Econ Manag. 2016;10:39.
   Google Scholar
• Bertram MY, Lauer JA, De Joncheere K, et al. Cost-effectiveness thresholds: pros and cons. Bull World Health Organ. 2016;94:925–930.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340:253–259.
   PubMed Web of Science ®Google Scholar
• Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372:375–382.
   PubMed Web of Science ®Google Scholar
• Strand V, Ahadieh S, French J, et al. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res Ther. 2015;17:362.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K, Gefeller O, et al. Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum. 2003;48:1530–1542.
   PubMed Web of Science ®Google Scholar
• Barton P, Jobanputra P, Wilson J, et al. The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technol Assess (Rockv). 2004;8:1–91.
   Web of Science ®Google Scholar
• Pennington B, Davis S. Mapping from the health assessment questionnaire to the eq-5d: the impact of different algorithms on cost-effectiveness results. Value Heal [Internet]. 2014;17:762–771.
   PubMed Web of Science ®Google Scholar
• Hernández Alava M, Wailoo AJ, Ara R. Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values. Value Heal [Internet]. 2012;15:550–561.
   PubMed Web of Science ®Google Scholar
• Jansen JP, Incerti D, Mutebi A, et al. Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators. J Med Econ. 2017;20:703–714.
   PubMed Web of Science ®Google Scholar
• Lee TJ, Park BH, Son HK, et al. Cost of illness and quality of life of patients with rheumatoid arthritis in South Korea. Value Heal. 2012;15:S43–S49.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Zwillich SH. The long-term outcomes of rheumatoid arthritis: A 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis. Arthritis Rheum. 1998;41:1072–1082.
   PubMed Web of Science ®Google Scholar
• Briggs A, Sculpher M, Claxton K Decision modelling for health economic evaluation [Internet]. Oxford University Press; 2006. Available from: http://econpapers.repec.org/RePEc:oxp:obooks:9780198526629.
   Google Scholar
• Claxton L, Taylor M, Soonasra A, et al. An economic evaluation of tofacitinib treatment in rheumatoid arthritis after methotrexate or after 1 or 2 TNF inhibitors from a U.S. Payer perspective. J Manag Care Spec Pharm. 2018;24:1010–1017.
   PubMed Web of Science ®Google Scholar
• Hernández Alava M, Wailoo A, Wolfe F, et al. The relationship between EQ-5D, HAQ and pain in patients with rheumatoid arthritis. Rheumatol (United Kingdom). 2013;52:944–950.
   PubMed Web of Science ®Google Scholar
• Hernández Alava M, Wailoo A, Wolfe F, et al. A comparison of direct and indirect methods for the estimation of health utilities from clinical outcomes. Med Decis Mak. 2014;34:919–930.
   PubMed Web of Science ®Google Scholar
• Diamantopoulos A, Benucci M, Capri S, et al. Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy. J Med Econ [Internet]. 2012;15:576–585. Available from: http://www.tandfonline.com/doi/full/10.3111/13696998.2012.665110
   PubMedGoogle Scholar
• Lee M, Park S, Park S, et al. Cost-effectiveness of tofacitinib in the treatment of moderate to severe rheumatoid arthritis in South Korea. Clin Ther. [Internet]. 2015;37:1662–1676.e2. .
   PubMed Web of Science ®Google Scholar
• Carlson JJ, Ogale S, Dejonckheere F, et al. Economic evaluation of tocilizumab monotherapy compared to adalimumab monotherapy in the treatment of severe active rheumatoid arthritis. Value Heal [Internet]. 2015;18:173–179.
   PubMed Web of Science ®Google Scholar
• Park S, Park S, Lee M, et al. Cost-effectiveness analysis of treatment sequence initiating with etanercept compared with le fl unomide in rheumatoid arthritis : impact of reduced etanercept cost with patent expiration in South Korea. Clin Ther [Internet]. 2016;1–20 . DOI:10.1016/j.clinthera.2016.09.016
   Web of Science ®Google Scholar
• Claxton L, Jenks M, Taylor M, et al. An economic evaluation of tofacitinib treatment in rheumatoid arthritis: modeling the cost of treatment strategies in the United States. J Manag Care Spec Pharm. [Internet]. 2016;22:1088–1102. Available from: http://www.jmcp.org/doi/10.18553/jmcp.2016.22.9.1088
   PubMedGoogle Scholar
• Stevenson M, Archer R, Tosh J, et al. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying. Health Technol Assess (Rockv) [Internet]. 2016;20:1–610. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27140438
   Web of Science ®Google Scholar
• Vieira MC, Wallenstein GV, Bradley JD, et al. FRI0185 Tofacitinib versus biologic treatments with and without methotrexate in patients with active rheumatoid arthritis who have had an inadequate response to traditional disease modifying anti-rheumatic drugs - a network meta-analysis. Ann Rheum Dis [Internet]. 2013;71:375.1–375. Available from: http://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2012-eular.2642
   Web of Science ®Google Scholar
• Taheri S, Mohammadzadeh H, Mehralian G. Cost-effectiveness analysis of tigecycline in comparison with imipenem/cilastatin or piperacillin/tazobactam in the treatment of complicated intra-abdominal infections: a perspective of iranian health systems. Value Heal. [Internet]. 2017;20:A789. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1098301517326463
   Web of Science ®Google Scholar
• Taheri S, Tahmasebi N. Cost-effectiveness analysis of long-acting recombinant FSH (Corifollitropin Alfa) versus recombinant FSH (Follitropin Alfa) in assisted reproduction techniques in the management of infertility in Iran. Value Heal. [Internet]. 2017;20:A521. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1098301517310318
   Web of Science ®Google Scholar
• Taheri S, Heidari E, Aivazi MA, et al. Cost-effectiveness analysis of ivabradine in treatment of patients with heart failure in Iran. Int J Technol Assess Health Care [Internet]. 2018;34:576–583. Available from: https://www.cambridge.org/core/product/identifier/S0266462318003598/type/journal_article
   PubMed Web of Science ®Google Scholar
• Taheri S, Mirzayeh Fashami F, Peiravian F, et al. Teriparatide in the treatment of severe postmenopausal osteoporosis: a cost-utility analysis. Iran J Pharm Res IJPR [Internet]. 2019;18:1073–1085. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31531089
   PubMed Web of Science ®Google Scholar
• Taheri S, Yousefi N, Sahraian M, et al. Cost-effectiveness analysis of alemtuzumab in comparison with natalizumab, intramuscular interferon beta-1a, subcutaneous interferon beta-1b, and fingolimod for the treatment of relapsing-remitting multiple sclerosis in Iran. Value Heal [Internet]. 2017;20:A723. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1098301517322805
   Web of Science ®Google Scholar
• Taheri S, Sahraian MA, Yousefi N. Cost-effectiveness of alemtuzumab and natalizumab for relapsing-remitting multiple sclerosis treatment in Iran: decision analysis based on an indirect comparison. J Med Econ. [Internet]. 2019;22:71–84. Available from: https://www.tandfonline.com/doi/full/10.1080/13696998.2018.1543189
   PubMed Web of Science ®Google Scholar
• Kobelt G. Thoughts on health economics in rheumatoid arthritis. Ann Rheum Dis. 2007;66:iii35–9. BMJ Publishing Group.
   PubMed Web of Science ®Google Scholar